Serum @entity9808 concentration as an aid to monitoring compliance with thyroid hormone therapy in XXXX .

@entity1 @entity1375 @entity9808 @entity1955 @entity1954
To monitor the compliance of @entity1 taking @entity1955 as replacement therapy for @entity1375 , the authors measured serum @entity9808 ( @entity9808 ), free @entity1955 index (FT4I), and free @entity1954 index (FT3I) in @entity1 attending the endocrine clinic. During a 6-month period, there were 159 visits by 132 @entity1 with @entity1375 . Five of the 132 @entity1 had @entity9808 levels greater than 12 microU/ml (normal, 0.3-5.7 microU/ml), with FT3I greater than 85 (normal, 70-160) and FT4I greater than 7 (normal, 4.2-11). Four others had @entity9808 greater than 6 microU/ml with normal FT3I and normal FT4I. These nine @entity1 had normal thyroid tests documented on replacement therapy in the past. Five of the nine admitted to discontinuing their medicine for more than 1 week or taking it erratically. Two untreated @entity1375 @entity1 had daily thyroid function tests after they were started on full replacement doses of @entity1955 . Both achieved FT4I greater than 4.2 by day 8 and FT3I greater than or equal to 70 by day 18, but serum @entity9808 concentration did not fall consistently below 20 microU/ml until day 23 in one @entity1 and day 21 in the other and did not fall to the normal range by discharge at day 37 in one @entity1 or day 42 in the other. Thus, although treatment with @entity1955 will normalize serum T4 and T3 concentrations within 3 weeks, normalization of serum @entity9808 may take several more weeks. This prospective study in a large out- @entity1 clinic shows that 4% of @entity1 with treated @entity1375 may have elevation of serum @entity9808 to more than twice the upper limit of normal, while serum T4 and T3 are clearly normal.(ABSTRACT TRUNCATED AT 250 WORDS)
